1166 related articles for article (PubMed ID: 18059005)
21. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
[TBL] [Abstract][Full Text] [Related]
22. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase.
Tuffery-Giraud S; Béroud C; Leturcq F; Yaou RB; Hamroun D; Michel-Calemard L; Moizard MP; Bernard R; Cossée M; Boisseau P; Blayau M; Creveaux I; Guiochon-Mantel A; de Martinville B; Philippe C; Monnier N; Bieth E; Khau Van Kien P; Desmet FO; Humbertclaude V; Kaplan JC; Chelly J; Claustres M
Hum Mutat; 2009 Jun; 30(6):934-45. PubMed ID: 19367636
[TBL] [Abstract][Full Text] [Related]
23. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
24. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center.
Takeshima Y; Yagi M; Okizuka Y; Awano H; Zhang Z; Yamauchi Y; Nishio H; Matsuo M
J Hum Genet; 2010 Jun; 55(6):379-88. PubMed ID: 20485447
[TBL] [Abstract][Full Text] [Related]
25. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
[TBL] [Abstract][Full Text] [Related]
26. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
[TBL] [Abstract][Full Text] [Related]
27. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
28. Point mutations in Czech DMD/BMD patients and their phenotypic outcome.
Sedlácková J; Vondrácek P; Hermanová M; Zámecník J; Hrubá Z; Haberlová J; Kraus J; Maríková T; Hedvicáková P; Vohánka S; Fajkusová L
Neuromuscul Disord; 2009 Nov; 19(11):749-53. PubMed ID: 19783145
[TBL] [Abstract][Full Text] [Related]
29. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene.
Deburgrave N; Daoud F; Llense S; Barbot JC; Récan D; Peccate C; Burghes AH; Béroud C; Garcia L; Kaplan JC; Chelly J; Leturcq F
Hum Mutat; 2007 Feb; 28(2):183-95. PubMed ID: 17041906
[TBL] [Abstract][Full Text] [Related]
30. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
[TBL] [Abstract][Full Text] [Related]
31. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.
Disset A; Bourgeois CF; Benmalek N; Claustres M; Stevenin J; Tuffery-Giraud S
Hum Mol Genet; 2006 Mar; 15(6):999-1013. PubMed ID: 16461336
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
33. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
[TBL] [Abstract][Full Text] [Related]
34. Mutation spectrum leading to an attenuated phenotype in dystrophinopathies.
Tuffery-Giraud S; Saquet C; Thorel D; Disset A; Rivier F; Malcolm S; Claustres M
Eur J Hum Genet; 2005 Dec; 13(12):1254-60. PubMed ID: 16077730
[TBL] [Abstract][Full Text] [Related]
35. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
36. Novel mutations of dystrophin gene in DMD patients detected by rapid scanning in biplex exons DHPLC analysis.
Muscarella LA; Piemontese MR; Barbano R; Fazio A; Guarnieri V; Quattrone A; Zelante L
Biomol Eng; 2007 Jun; 24(2):231-6. PubMed ID: 17145200
[TBL] [Abstract][Full Text] [Related]
37. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
38. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
39. Pure intronic rearrangements leading to aberrant pseudoexon inclusion in dystrophinopathy: a new class of mutations?
Khelifi MM; Ishmukhametova A; Khau Van Kien P; Thorel D; Méchin D; Perelman S; Pouget J; Claustres M; Tuffery-Giraud S
Hum Mutat; 2011 Apr; 32(4):467-75. PubMed ID: 21305657
[TBL] [Abstract][Full Text] [Related]
40. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
